Poolbeg Pharma, a biopharmaceutical company that specialises in infectious diseases, has filed a patent for one of its treatments to be used in cancer treatments.
The treatment, called POLB 001, was developed to address severe influenza, but it has been found to have the potential to address life-threatening side effects in cancer treatment as well.
The London-based Irish company announced that while investigating the role of cytokine release syndrome (CRS) in severe influenza, it discovered data specific to the overt immune response in CAR T cell patients that suggest POLB 001 as a potential treatment.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. POLB 001 has the potential to dampen the pro-inflammatory cytokine release syndrome affecting patients receiving CAR T cell therapies
